Nanoparticles (NPs) for cancer therapeutics are rapidly evolving and are being introduced in an attempt to overcome several limitations of conventional small-molecule chemotherapeutics. Though chemotherapy is successful to some extent in certain cancers, it has several limitations. Among the main drawbacks of chemotherapy are the lack of sufficient selectivity to the neoplasia and consequent toxicity to healthy tissues, limited bioaccessibility and bioavailability of drugs to the tumour tissues, hence that require a high dosage of drugs.